To explore the possibility that serum PL85 may have a mix of antibodies, including anti-DFS70/LEDGFp75 antibodies, despite a CLIA negative result, we performed immunoblotting analysis using total proteins from the docetaxel-resistant prostate cancer cell line PC3-DR, which we previously demonstrated to overexpress DFS70/LEDGFp75 [50]. This evidence concerns the gene PSIP1 and prostate cancer.